On the evening of March 19, Bloomage Biotech announced that the company is undergoing a management restructuring. To adjust its management framework in alignment with strategic development needs, the company’s general manager proposed changes to the roles of some senior executives and appointed new senior management personnel as required for business operations.
According to the announcement, the roles of three vice presidents—Liu Aihua, Xu Guixin, and Luan Yizheng—have been adjusted, while two new vice presidents, Wang Hui and Xiang Maogong, have been appointed. Bloomage Biotech stated that since Liu Aihua has exceeded the statutory retirement age and had signed a reemployment contract upon retirement, this contract is set to expire soon and will not be renewed. Consequently, Liu Aihua will no longer serve as vice president and will not hold any further position within the company.
Additionally, Bloomage Biotech emphasized that as part of the management restructuring, the company has decided to reduce the number of vice president positions that are not legally required to streamline the management hierarchy. Xu Guixin and Luan Yizheng will no longer serve as vice presidents or be classified as senior executives but will remain with the company as business vice presidents.
Public records show that Liu Aihua, born in 1963, holds a bachelor’s degree in pharmaceutical preparation from Shenyang Pharmaceutical University. She served as the general manager of Bloomage Freda from December 2002 to April 2016, vice president of Bloomage International Investment Group Co., Ltd. from May 2016 to March 2018, and vice president of Bloomage Biotech since April 2018.
Luan Yizheng, born in 1985, holds a graduate degree in accounting from Tsinghua University’s School of Economics and Management. He has previous experience at UBS Securities, Hony Capital, and Hillhouse Capital. Since joining Bloomage Biotech in 2019, he has served as general manager of the finance center and financial director and is currently a vice president of the company.
Xu Guixin, born in 1972, holds a graduate degree from Renmin University of China. He has held various positions at the company, including materials department manager, sales department manager, sales director, deputy general manager of sales, executive vice president, and vice president.
Regarding stock holdings, as of the announcement date, Liu Aihua held 70,800 shares of Bloomage Biotech, Xu Guixin held 44,160 shares, and Luan Yizheng held 55,200 shares.
In terms of new appointments, Bloomage Biotech announced that, based on operational management needs, the company has appointed Wang Hui and Xiang Maogong as vice presidents.
According to their disclosed resumes, Wang Hui, born in 1983, holds a master’s degree in industrial engineering from Tsinghua University. He joined Bloomage Biotech in September 2023 and currently serves as the company’s financial director, overseeing financial management.
Xiang Maogong, also born in the 1980s (1984), holds a graduate degree in microbiology and biochemical pharmacy from Shandong University. He has previously worked at Lunan Pharmaceutical Group, Haida Boyuan, and Zhongshan Biotechnology. Since joining Bloomage Biotech in March 2021, he has been the executive director of the global supply chain platform and a key technical personnel, responsible for managing the global supply chain.
As of the announcement date, neither Wang Hui nor Xiang Maogong held any company shares.
According to Bloomage Biotech’s recently released performance report, the company’s total revenue for 2024 was RMB 5.371 billion, marking an 11.60% year-over-year decline. Net profit attributable to the parent company was RMB 164 million, representing a sharp 72.27% decrease. This marks the first time since Bloomage Biotech’s IPO on November 6, 2019, that the company has experienced a double-digit decline in both revenue and net profit.
Amidst the poor financial performance, on the evening of March 3, 2025, Bloomage Biotech’s official WeChat account published a speech by Chairwoman Zhao Yan during a company executive meeting, which sparked widespread discussion due to its strong wording. During the meeting, Zhao Yan announced a major organizational overhaul, stating that the company would take decisive action to address historical issues. She declared a zero-tolerance policy for corruption, demanding that all employees involved, regardless of rank, confess their misconduct and submit their resignations by March 31.
Zhao Yan emphasized that while market conditions have contributed to Bloomage Biotech’s recent performance fluctuations, the company’s primary challenge lies in its organizational structure and talent management failing to adapt to industry changes, leading to developmental bottlenecks. She identified the root issue as an excessive increase in organizational entropy rather than just declining financial performance, necessitating a comprehensive restructuring of the company’s management framework.
She further stressed that as an entrepreneur, she would not tolerate any actions that disrupt company order. “We need to build a young, hardcore professional team with an exploratory spirit—people who strive because they believe, and because of that belief, they create new opportunities and a new world,” she stated.
